Earlier in May 2026, Arrowhead Pharmaceuticals reported a sharp drop in quarterly sales to US$73.74 million and moved from net income to a net loss of US$132.73 million, while also filing a roughly US...
Source LinkEarlier in May 2026, Arrowhead Pharmaceuticals reported a sharp drop in quarterly sales to US$73.74 million and moved from net income to a net loss of US$132.73 million, while also filing a roughly US...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.